Compare BWAY & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWAY | EOLS |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.5M | 550.9M |
| IPO Year | 2011 | 2018 |
| Metric | BWAY | EOLS |
|---|---|---|
| Price | $16.89 | $8.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $13.25 | ★ $15.50 |
| AVG Volume (30 Days) | 157.5K | ★ 949.9K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | $309.69 | $13.27 |
| Revenue Next Year | $26.21 | $17.62 |
| P/E Ratio | $81.98 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $11.77 | $3.86 |
| 52 Week High | $26.63 | $8.43 |
| Indicator | BWAY | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 60.51 | 74.84 |
| Support Level | $14.13 | $6.44 |
| Resistance Level | $18.05 | N/A |
| Average True Range (ATR) | 0.90 | 0.39 |
| MACD | 0.09 | 0.27 |
| Stochastic Oscillator | 84.05 | 95.13 |
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.